These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 34015411

  • 1. Obscurin: A multitasking giant in the fight against cancer.
    Guardia T, Eason M, Kontrogianni-Konstantopoulos A.
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188567. PubMed ID: 34015411
    [Abstract] [Full Text] [Related]

  • 2. Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer.
    Tuntithavornwat S, Shea DJ, Wong BS, Guardia T, Lee SJ, Yankaskas CL, Zheng L, Kontrogianni-Konstantopoulos A, Konstantopoulos K.
    Cancer Lett; 2022 Feb 01; 526():155-167. PubMed ID: 34826548
    [Abstract] [Full Text] [Related]

  • 3. Unraveling obscurins in heart disease.
    Grogan A, Kontrogianni-Konstantopoulos A.
    Pflugers Arch; 2019 May 01; 471(5):735-743. PubMed ID: 30099631
    [Abstract] [Full Text] [Related]

  • 4. OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer.
    Guardia T, Zhang Y, Thompson KN, Lee SJ, Martin SS, Konstantopoulos K, Kontrogianni-Konstantopoulos A.
    Proc Natl Acad Sci U S A; 2023 Mar 14; 120(11):e2215553120. PubMed ID: 36877839
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance.
    Perry NA, Shriver M, Mameza MG, Grabias B, Balzer E, Kontrogianni-Konstantopoulos A.
    FASEB J; 2012 Jul 14; 26(7):2764-75. PubMed ID: 22441987
    [Abstract] [Full Text] [Related]

  • 7. Obscurins: unassuming giants enter the spotlight.
    Perry NA, Ackermann MA, Shriver M, Hu LY, Kontrogianni-Konstantopoulos A.
    IUBMB Life; 2013 Jun 14; 65(6):479-86. PubMed ID: 23512348
    [Abstract] [Full Text] [Related]

  • 8. Obscurins: Goliaths and Davids take over non-muscle tissues.
    Ackermann MA, Shriver M, Perry NA, Hu LY, Kontrogianni-Konstantopoulos A.
    PLoS One; 2014 Jun 14; 9(2):e88162. PubMed ID: 24516603
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel OBSCN variants associated with a risk to exercise-intolerance and rhabdomyolysis.
    Zemorshidi F, Töpf A, Claeys KG, McFarlane A, Patton A, Nafissi S, Straub V.
    Neuromuscul Disord; 2024 Jan 14; 34():83-88. PubMed ID: 38159459
    [Abstract] [Full Text] [Related]

  • 13. Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells.
    Perry NA, Vitolo MI, Martin SS, Kontrogianni-Konstantopoulos A.
    Oncotarget; 2014 Sep 30; 5(18):8558-68. PubMed ID: 25261370
    [Abstract] [Full Text] [Related]

  • 14. A comprehensive genomic meta-analysis identifies confirmatory role of OBSCN gene in breast tumorigenesis.
    Rajendran BK, Deng CX.
    Oncotarget; 2017 Nov 24; 8(60):102263-102276. PubMed ID: 29254242
    [Abstract] [Full Text] [Related]

  • 15. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway.
    Qiao K, Ning S, Wan L, Wu H, Wang Q, Zhang X, Xu S, Pang D.
    J Exp Clin Cancer Res; 2019 Oct 17; 38(1):418. PubMed ID: 31623640
    [Abstract] [Full Text] [Related]

  • 16. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
    Liu Z, Wang L, Guo C, Liu L, Jiao D, Sun Z, Wu K, Zhao Y, Han X.
    J Cell Mol Med; 2021 Apr 17; 25(7):3239-3251. PubMed ID: 33624434
    [Abstract] [Full Text] [Related]

  • 17. Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers.
    Kang L, Sun J, Wen X, Cui J, Wang G, Hoffman AR, Hu JF, Li W.
    Eur J Cancer; 2015 Jan 17; 51(2):260-70. PubMed ID: 25465188
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Obscurin variants and inherited cardiomyopathies.
    Marston S.
    Biophys Rev; 2017 Jun 17; 9(3):239-243. PubMed ID: 28510120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.